Collagen and elastin degradation products as potential activity markers of scleroderma
Authors:
R. Bečvář; J. Štork 1; H. Hulejová; M. Braun; I. Zatloukalová 2; P. Zatloukal 3; P. Jansa 4; T. Paleček 4
Authors‘ workplace:
Revmatologický ústav, Klinika revmatologie 1. lékařská fakulta Univerzity Karlovy, Praha
; Dermatovenerologická klinika, Všeobecná fakultní nemocnice a 1. lékařská fakulta Univerzity Karlovy, Praha
1; Nestátní pneumologické zařízení, Poliklinika Kartouzská, Praha
2; Klinika pneumologie a hrudní chirurgie, Fakultní nemocnice Na Bulovce a 3. lékařská fakulta Univerzity Karlovy a IPVZ, Praha
3; 2. interní klinika kardiologie a angiologie Všeobecné fakultní nemocnice a 1. lékařské fakulty Univerzity Karlovy, Praha
4
Published in:
Čes. Revmatol., 17, 2009, No. 1, p. 23-29.
Category:
Original Papers
Overview
Introduction.
Systemic (SSc) and localized scleroderma (LSc) do not have reliable activity markers. In both conditions an excessive deposition of collagen and elastin fibrils occurs in the skin and subcutis, and in SSc additionally in vessel walls and in majority of parenchymatous organs.
Aims.
The aim of this study was to assess the degradation of collagen type I, elastin excretion and proinflammatory cytokines in SSc and LSc compared with patients with psoriasis vulgaris (PsV) and healthy controls (HC).
Patients and methods.
Total 91 individuals were examined – 24 with SSc, 16 with LSc, and two control groups - 37 patients with PsV and 14 blood donors. Urinary excretion of pyridinoline (U-PD) and deoxypyridinoline (U-DPD) were measured using sensitive isocratic HPLC method. Urinary excretion of soluble elastin (U-SE) ) was evaluated by quantitative immunoprecipitation method, serum levels of interleukin-6 (IL-6) and soluble interleukin-2 receptor (IL-2R) were assayed using commercial ELISA kits. All measurements were performed at entry and after one year.
Results.
U-PD levels were the highest at entry and after one year in SSc group. At entry U-PD concentrations in SSc and LSc groups were increased compared with HC (p < 0.0001, and p < 0.0001 respectively). SSc patients had also a higher levels compared with PsV group (p < 0.001). At entry U-DPD levels in SSc group were increased compared with HC and LSc (p = 0.006, and p < 0.001 respectively). U-SE was the highest at entry in PsV and one year later in SSc group. At entry U-SE in PsV group were increased compared with HC (p < 0.001). After a year U-SE in SSc and PsV patients were higher compared with HC (for both p = 0.001). IL-6 serum levels were increased at entry in SSc, LSc and PsV groups compared with HC (p < 0.0001, p < 0.001, and p = 0.004 respectively), after one year only SSc had increased levels compared with HC (p < 0.001). IL-2R serum levels did not differ among the studied groups at any time.
Conclusions.
The increased markers of collagen and elastin turnover in SSc and LSc reflect the active fibrotic process in the diseases and are accordance with the published data. High elastin levels in PsV group are surprising, and we have so far no explanation for this result.
Key words:
systemic sclerosis, morphea, psoriasis, collagen, elastin, activity
Sources
1. Medsger TA. Comment on scleroderma criteria cooperative study. In: Black CM and Myers AR (eds): Systemic sclerosis (Scleroderma). 1st ed. New York, Gower Med 1985: 235-49.
2. LeRoy EC, Black CM, Fleischmajer R, et al. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 1988; 15: 202-5.
3. Kahaleh MB, LeRoy EC. Interleukin-2 in scleroderma: correlation of serum levels with extent of skin involvement and disease duration. Ann Intern Med 1989; 110: 446-50.
4. Jablonska S, et al. Localized scleroderma. In: Jayson MIV, Black CM. Systemic sclerosis: scleroderma. 1. ed. Chichester, Willey, 1988: 303-18.
5. Štork J. Klasifikace sklerodermia circumscripta. Čs Derm 1991; 66: 331-5.
6. Farber EM, Raychaudhuri SP. Is psoriasis a neuroimmunologic disease? Int J Derm 1999; 38: 12-5.
7. Prinz JC. Which T cells cause psoriasis? Clin Exp Dermatol 1999; 24: 291-5.
8. Hunzelmann N, Risteli J, Risteli L, et al. Circulating type I collagen degradation products: a new serum marker for clinical severity in patients with scleroderma? Brit J Dermatol 1998; 139: 1020-5.
9. Baruffo A, Abbadessa A, Maja L, Tirri R, La Montagna G. Increased levels of urinary pyridinium crosslinks of collagen in systemic sclerosis. Conn Tiss Dis 1993; XII:47-57.
10. Steinert PM. The complexity and redundancy of epithelial barrier function. J Cell Biol 2000; 151: F5-7.
11. Špaček P, Hulejová H, Adam M. Ion exchange determination of pyridium crosslinks in urine as markers of bone resorption. J Liq Chrom Rel Tech 1997; 20: 1921-30.
12. Maricq HR. Nailfold capillaroscopy and biopsy in scleroderma and related disorders. Dermatologica 1984; 168: 73-7.
13. Bečvář R, Štork J, Pešáková V, Stáňová A, Hulejová H, Rysová L, Zatloukalová A, Zatloukal P, Jáchymová M, Pourová L. Klinické korelace potenciálních ukazatelů aktivity systémové sklerodermie. Čes Revmatol 2003; 11: 128-137.
14. Rodnan GP, Lipinski E, Luksick J. Skin thickness and collagen content in progressive systemic sclerosis and localized scleroderma. Arthritis Rheum 1979; 22: 130-40.
15. Seyger MM, va den Hoogen FH, de Boo T, de Jong EM. Reliability of two methods to assess morphea skin scoring and the use of durometer. J Am Acad Dermatol 1997; 37: 793-6.
16. Becvar R, Stork J, Pesakova V, et al. Clinical correlations of potential activity markers in systemic sclerosis. Ann N Y Acad Sci 2005; 1051: 404-12.
17. Ištok R, Czirják L, Lukáč J, Stančíková M, Rovenský J. Increased urinary pyridinoline cross-link compounds of collagen in patients with systemic sclerosis and Raynaud’s phenomenon. Rheumatology 2001; 40: 140-6.
18. Ištok R, Bely M, Stančíková M, Rovenský J. Evidence for increased pyridinoline concentration in fibrotic tissues in diffuse systemic sclerosis. Clin Exp Dermatol 2001; 26: 545-7.
19. Brinckmann J, Neess CM, Gaber Y, et al. Different pattern of collagen cross-links in two sclerotic skin diseases: lipodermatosclerosis and circumscribed scleroderma. J Invest Dermatol 2001; 117: 269-73.
20. Stone PJ, Korn JH, North H, et al. Cross-linked elastin and collagen degradation products in the urine of patients with scleroderma. Arthritis Rheum 1995; 38: 517-24.
Labels
Dermatology & STDs Paediatric rheumatology RheumatologyArticle was published in
Czech Rheumatology
2009 Issue 1
Most read in this issue
- Interleukin 6 in rheumatic diseases
- News in the biological therapy of rheumatoid arthritis and future prospects
- Rituximab in the treatment of Wegener’s granulomatosis non-responsive to standard therapy
- Collagen and elastin degradation products as potential activity markers of scleroderma